Answer :
Answer:
The decision to permanently discontinue immune checkpoint inhibitors (ICIs) depends on various factors, as the severity and type of adverse event, as well as the patient's overall health and underlying condition being treated.
Explanation:
However, in general, grade 4 irAEs, which are considered severe or life-threatening, often require permanent discontinuation of the immune checkpoint inhibitor. These severe adverse events may include conditions such as pneumonitis, colitis, hepatitis, nephritis, myocarditis, or neurologic toxicities
Grade 3 irAEs, which are considered severe but not immediately life-threatening, may also lead to discontinuation of the immune checkpoint inhibitor, depending on the specific toxicity, duration, and how it responds to treatment.
